Giovanni Rubino

Siena, 53100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Neurocognitive and neuropsychiatric presentation identifies a higher-risk clinical phenotype in IDH-wildtype glioblastoma: A retrospective cohort study.

Neurocognitive and neuropsychiatric presentation identifies a higher-risk clinical phenotype in IDH-wildtype glioblastoma: A retrospective cohort study.

Journal: Clinical neurology and neurosurgery

Published: July 09, 2026

Reduced Clinical Target Volume Margins in Glioblastoma: Exploratory Evidence Supporting Further Margin Reduction Independent of MGMT Status.

Reduced Clinical Target Volume Margins in Glioblastoma: Exploratory Evidence Supporting Further Margin Reduction Independent of MGMT Status.

Journal: Brain sciences

Published: March 30, 2026

Beyond Resection: Surgery as an Evolutionary Bottleneck Shaping Tumor Evolution and Treatment Response in Diffuse Gliomas.

Beyond Resection: Surgery as an Evolutionary Bottleneck Shaping Tumor Evolution and Treatment Response in Diffuse Gliomas.

Journal: Cancers

Published: February 16, 2026

A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

Journal: Cancers

Published: December 12, 2025

Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups.

Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups.

Journal: Journal of neuro-oncology

Published: July 18, 2025

Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide.

Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide.

Journal: Brain sciences

Published: May 31, 2025

Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol.

Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol.

Journal: Journal of neuro-oncology

Published: September 28, 2024

Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.

Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.

Journal: Journal of neuro-oncology

Published: September 27, 2024

Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.

Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.

Journal: Journal of neuro-oncology

Published: August 09, 2024

Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low-Middle Income Countries: A Narrative Review.

Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low-Middle Income Countries: A Narrative Review.

Journal: Cancers

Published: July 23, 2024

3D bone texture analysis as a potential predictor of radiation-induced insufficiency fractures.

3D bone texture analysis as a potential predictor of radiation-induced insufficiency fractures.

Journal: Quantitative imaging in medicine and surgery

Published: March 16, 2018

Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Journal: La Radiologia medica

Published: July 14, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026